Home  /  Resource Library  /  Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

ASH 2020: Results of a study investigating zanubrutinib for first line treatment of CLL in patients with 17p deletion.